Skip to main content

Table 1 Characteristics of the studies included in this meta-analysis

From: Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Study Region Year Type of DM No. of DM patients No. of healthy controls Mean age of DM patients Mean age of healthy controls Diagnosis criteria Method
Jian Li et al. [15] China 2015 GDM 35 43 29.3 ± 3.1 30.6 ± 3.8 ADA 2012 ELISA (Quidel, USA)
Rathcke et al. [16] Denmark 2005 T2DM 87 158 54.2 (40–70)a NA National Diabetes Data Group 1979 ELISA (Quidel, USA)
Thomsen et al. [17] Denmark 2010 T2DM 45 20 54 (41–73)b 50 (34–66)b NA ELISA (Quidel, USA)
Schaller et al. [18] Austria 2010 GDM 28 30 33 ± 6 33 ± 4 ADA criteria for GDM 2004 ELISA (Quidel, USA)
Sakamoto et al. [19] Japan 2013 T1DM 131 97 24.7 ± 5.9 25.5 ± 2.7 NA ELISA (Quidel, USA)
Rinnov et al. [20] Denmark 2015 GDM 10 8 31.1 ± 5.6 28.1 ± 1.8 OGTT 2 h GLU ≥ 9.0 mM ELISA (Quidel, USA)
Abd El Dayem et al. [21] Egypt 2015 T1DM 62 30 16.32 ± 1.52 16.13 ± 2.63 NA ELISA (Quidel, USA)
Shiasi et al. [22] Iran 2017 T1DM 49 43 12.20 ± 3.86 10.95 ± 3.83 ADA ELISA (Quidel, USA)
Rekha Kumari et al. [23] India 2015 T2DM 30 30 44.4 ± 2.7 45.95 ± 3.4 NA ELISA
Song Wei et al. [24] China 2015 T2DM 210 210 58.29 ± 5.94 59.98 ± 7.53 NA ELISA (Quidel, USA)
Ye Kejun et al. [25] China 2016 GDM 50 50 27.2 ± 3.4 28.6 ± 3.8 ADA 2005 ELISA
Chen Qingfu et al. [26] China 2014 T2DM 48 45 NA 48.1 ± 13.7 WHO 1999 ELISA (Quidel, USA)
Li Peng et al. [27] China 2011 T2DM 41 40 54.61 ± 12.37 42.8 ± 13.52 NA ELISA (Becton,Dickinson and Company, USA)
Lin Lijun et al. [28] China 2019 T2DM 42 40 NA NA NA ELISA
Xun Shengli et al. [29] China 2017 GDM 60 20 27.85 ± 4.48 26.82 ± 3.10 Obstetrics and gynecology [M] ELISA
Yu Yeye et al. [30] China 2018 T2DM 60 60 46.48 ± 11.54 47.83 ± 9.68 ADA 2007 ELISA
Ren Lijue et al. [31] China 2019 T2DM 30 30 57.20 ± 10.30 54.5 ± 10.44 WHO 1999 ELISA
Rathcke et al. [32] Denmark 2009 T1DM 58A/46B/45C 55 55.6 ± 10.8A/54 ± 11.1B/49 ± 9.6C 50.5 ± 10.9 NA ELISA (Quidel, USA)
Røndbjerg et al. [33] Denmark 2011 T2DM 49A/35B/21C 20 61.3 ± 12.0A/60.1 ± 11.7B/64 ± 13.1C 57.1 ± 7.2 NA ELISA (Quidel, USA)
Lee et al. [34] South Korea 2012 T2DM 25A/25B/25C 22 55.6 ± 11.1A/57.0 ± 11.6B/56.0 ± 9.8C 52.4 ± 5.8 NA ELISA
Han et al. [13] China 2015 T2DM 260A/246B/232C 210 52.83 ± 4.30A/53.93 ± 4.56B/ 53.93 ± 4.22C 53.40 ± 4.28 ADA 2007 ELISA (Bio-Technology Co. Ltd., USA)
Umapathy et al. [35] India 2018 T2DM 81A/73B/69C 83 54.07 ± 11.09A/55.1 ± 10.9B/57.39 ± 5.39C 52.59 ± 12.9 NA a multiplex bead-based assay system (Bio-Rad, Hercules, California, USA)
Zhu Huijing et al. [36] China 2015 T2DM 23A/24B/23C 20 63.00 ± 13.76A/65.33 ± 9.13B/66.35 ± 7.84C 62.0 ± 11.16 ADA 2007 ELISA
Wang Huan et al. [37] China 2015 T2DM 21B/39C 30 NA 68 ± 8 NA ELISA (Quidel, USA)
Yu Zhixuan et al. [38] China 2017 T2DM 30A/30B 30 NA 55.45 ± 7.36 NA ELISA
  1. T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, GDM gestational diabetes mellitus, ADA, American Diabetes Association, WHO World Health Organization, ELISA enzyme linked immunosorbent assay, NA Not available
  2. ADM patients with normoalbuminuria,
  3. BDM patients with microalbuminuria
  4. CDM patients with macroalbuminuria
  5. aMean/range
  6. bMedian/range